Product information and disease descriptionProduct description
Phase of product development
13 evidence topics · 16 sources
Regulatory status: Submission planned; BLA planned for 2027
Launch
No evidence found.
Development phase: phase 3, with phase 3 treatment continuing to 52 weeks
Additional phase 3 results anticipated in February 2027
Phase 3 topline results reported in September 2026
Phase 3 enrollment completed in February 2026
Phase 3 trials initiated in July 2024
Phase 2 study: first participant dosed in June 2022
Subcutaneous formulation phase 1 study in healthy volunteers: first cohort dosed in September 2021
Phase 1b study in chronic spontaneous urticaria: first participant dosed in October 2020
Development in other indications: cold urticaria, symptomatic dermographism, atopic dermatitis, prurigo nodularis, and eosinophilic esophagitis
FDA expedited program designations for chronic spontaneous urticaria
No evidence found.